Skip to main content
OpenTrials
Completed

NCT Number: NCT04757454

Performance Indicators of the SARC-F Questionnaire in Acute Care

The study applies the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs, Falls (SARC-F) questionnaire in older patients hospitalized in an acute care geriatric unit and aims to determine its performance indicators to screen for sarcopenia according to the revised European Consensus on definition and diagnosis (EWGSOP2) within this population

Completed

Looking for future studies?

Notify Me

Key information

About this study

Sarcopenia is an age-related disease associated with health adverse outcomes, i.e. higher risk of mobility limitation, falls, fractures, mortality, and lower quality of life. The European Working Group on Sarcopenia has recently revisited one of the widely used most acknowledged definitions and launched the revised European consensus on definition and diagnosis (EWGSOP2) (4). Applying the EWGSOP2 is a three-tier process: first, screening by the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs, Falls (SARC-F) questionnaire; second, diagnosis by low muscle strength, and low muscle mass; third, severity grading by low muscle function. The EWGSOP2 recommends the assessment of sarcopenia in every population, both in community-dwelling and acute care older patients. However, the evidence about the performance indicators of the SARC-F questionnaire to screen for sarcopenia in acute patients admitted to an acute care unit is really limited.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 65 and over
  • Hospitalized in an acute care geriatric unit due to acute health issues or acute medical conditions
  • With SARC-F, hand-grip strength and dual-energy X-ray absorptiometry administered during hospital admission

Exclusion criteria

  • SARC-F unavailable
  • Unwilling to collaborate in the sarcopenia assessment
  • Unwilling to sign the informed consent

Treatment and study plan

5-item SARC-F questionnaire

Diagnostic Test

Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit

Primary outcomes

  1. Sensitivity of the SARC-F questionnaire as screening method compared to the gold standard, which is the revised European consensus on definition and diagnosis

    Time frame: September 2019-November 2020

    Sensitivity, measured as a percentage (%)

  2. Specificity of the SARC-F questionnaire as a screening method, compared to the gold standard which is the revised European Consensus on definition and diagnosis of sarcopenia (EWGSOP2)

    Time frame: September 2019-November 2020

    Specificity, measured as a percentage (%)

  3. Overall concordance agreement between the SARC-F questionnaire as a screening method and the gold standard method, which is the EWGSOP2

    Time frame: September 2019-November 2020

    Cohen-kappa coefficient, measured as a percentage (%)

Secondary outcomes

  1. Health adverse outcomes based on the screening and diagnosis of sarcopenia as recommended by the EWGSOP2

    Time frame: 1-year follow-up

    Mortality risk

Sponsors and collaborators

Lead sponsor

Brugmann University Hospital

Other

Registry information

Acronym: SARC-F-CHUB

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Feb 17, 2021
Registry last updated
Feb 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.